Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of “Moderate Buy” by Analysts

Zura Bio Limited (NASDAQ:ZURA) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $11.60.

A number of brokerages have commented on ZURA. Wedbush started coverage on shares of Zura Bio in a research note on Monday, February 9th. They set an “outperform” rating and a $15.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Finally, Leerink Partners upgraded shares of Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd.

Zura Bio Stock Performance

Shares of Zura Bio stock opened at $6.12 on Friday. The stock has a market capitalization of $397.92 million, a PE ratio of -9.42 and a beta of 0.18. Zura Bio has a 52 week low of $0.97 and a 52 week high of $7.44. The stock has a 50 day moving average price of $6.16 and a two-hundred day moving average price of $4.51.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Tuesday, March 24th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). Research analysts forecast that Zura Bio will post -0.65 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of the business’s stock in a transaction on Thursday, February 26th. The stock was acquired at an average price of $6.25 per share, for a total transaction of $12,500,000.00. Following the purchase, the insider owned 6,552,725 shares of the company’s stock, valued at approximately $40,954,531.25. This trade represents a 43.93% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 14.23% of the company’s stock.

Institutional Trading of Zura Bio

Several institutional investors and hedge funds have recently modified their holdings of ZURA. Suvretta Capital Management LLC boosted its position in shares of Zura Bio by 1.7% during the fourth quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock valued at $29,171,000 after buying an additional 94,110 shares during the last quarter. VR Adviser LLC raised its position in Zura Bio by 15.4% in the 4th quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock valued at $28,008,000 after buying an additional 713,899 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after acquiring an additional 2,052,732 shares in the last quarter. Braidwell LP lifted its stake in Zura Bio by 28.6% during the 4th quarter. Braidwell LP now owns 3,180,389 shares of the company’s stock valued at $16,665,000 after acquiring an additional 707,583 shares in the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in Zura Bio by 42.3% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,813,671 shares of the company’s stock worth $9,504,000 after acquiring an additional 539,320 shares during the last quarter. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.